Etoposide as Salvage Therapy for Cytokine Storm due to COVID-19

Thumbnail
Name:
Patel-PrePrint-2020.pdf
Size:
161.8Kb
Format:
PDF
Download
Genre
Pre-print
Date
2020-09-12
Author
Patel, Maulin
Dominguez Castillo, Eduardo cc
Sacher, Daniel cc
Desai, Parag
Chandar, Ashwin
Bromberg, Michael
Caricchio, Roberto cc
Criner, Gerard J.
Group
COVID-19 Research Group (Temple University)
Department
Thoracic Medicine and Surgery
Hematology and Oncology
Rheumatology
Subject
COVID-19
Etoposide
Permanent link to this record
http://hdl.handle.net/20.500.12613/4153

Metadata
Show full item record
DOI
https://doi.org/10.1016/j.chest.2020.09.077
Abstract
Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators therapies. We present a unique case of severe cytokine storm resistant to multiple anti-cytokine therapies, but eventually responsive to etoposide. Thus, etoposide may have a role as salvage therapy in treatment of cytokine storm in COVID-19. To our knowledge, this is the first reported case of use of etoposide in COVID-19.
Citation to related work
Elsevier
Has part
Chest
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Collections